India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.
The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.
A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.
Pfizer Inc said last week a redesigned COVID-19 vaccine that specifically targets the Omicron coronavirus variant could be ready to launch by March.
The source said Gennova on Friday separately submitted to India's drug regulator phase 2 trial data for its original mRNA vaccine candidate. The government said last year that product was found to be "safe, tolerable, and immunogenic" in the participants of an initial study.
If given emergency-use approval, this would be the country's first mRNA COVID-19 vaccine like the ones developed by Pfizer and Moderna.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
US Lawmakers Back Covid Chinese Lab Leak Theory After Two-Year Probe New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Study Shows How Long Covid Is Debilitating Children's Health Bengaluru Techie Loses Rs 11.8 Crore After "Digital Arrest" "Daughter Doesn't Know Her Mother's Dead": 'Pushpa 2' Stampede Victim's Husband Kolkata Man Gets Divorce As "Imposition Of Wife's Friend" Is Deemed Cruelty "It Pains My Heart...": PM Cites Germany, Lanka Attacks At Christmas Event Illegal Migrant: Delhi Schools Ordered To Follow Strict Admission Process CBI Comes Up With 'Bharatpol' For Coordination With States, Agencies Track Latest News Live on NDTV.com and get news updates from India and around the world.